Business news, market intelligence, and global industry analysis.
The Latest

Dr. Reddy’s Laboratories launches sorafenib generic in US

bySrinath
June 14, 2022
1 minute read
Total
0
Shares
0
0
0

Dr. Reddy’s Laboratories said that it has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market following the approval of the US Food and Drug Administration (FDA).

Dr. Reddy’s Sorafenib Tablets, USP, 200 mg is a generic of Bayer HealthCare Pharmaceuticals’ cancer drug Nexavar (sorafenib). The product will be available in 200 mg tablets in bottle count sizes of 120, said Dr. Reddy’s Laboratories.

Dr. Reddy’s Laboratories launches sorafenib generic in US
Dr. Reddy’s Laboratories launches sorafenib generic in US. Photo courtesy of Karthikndr/Wikimedia Commons.

Marc Kikuchi — Dr. Reddy’s Laboratories North America Generics CEO said: “We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients.”

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Hanx Biopharmaceuticals set to begin US clinical trial of HX009 in lymphoma
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Celgene bags Inrebic FDA approval for myelofibrosis

Inrebic FDA approval : Celgene’s subsidiary Impact Biomedicines, has bagged approval for its oral kinase inhibitor Inrebic (fedratinib) capsules from the US Food and Drug Administration (FDA) for the treatment of certain types of myelofibrosis, a rare bone marrow cancer. Fedratinib FDA approval is for the treatment of adult patients with intermediate-2 or high-risk primary […]

The post Celgene bags Inrebic FDA approval for myelofibrosis appeared first on PharmaNewsDaily.com.

bypharmanewsdaily